You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
SBC: 7 Hills Pharma LLC Topic: 102Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing an automated yeast dissection system for aging research
SBC: Innovative BioChips LLC Topic: NIAPROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Create Ultralong DNA Constructs in One Assembly Step
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: 400Create Ultralong DNA Constructs in One Assembly Step Firebird Biomolecular Sciences LLCSteven ABenner Foundation for Applied Molecular EvolutionShuichi Hoshika AbstractFrost andampSullivan found aglobal market for DNA oligos at $million$million for genesPrivate investment in DNA synthesis companies like TwistGinkgoand DNA Script give collective valuations of several billion dollarsFederal public i ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
ADULT HUMAN PROGENITOR CELLS FOR CARDIAC REGENERATION
SBC: KARDIA THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): This proposal is the Phase II renewal of an STTR award to Kardia Therapeutics undertaken in collaboration with Baylor College of Medicine (the home to Kardia's founding scientists). The project will accelerate the development and commercialization of human heart-derived cardiac progenitor cells (CPCs), to promote more effective regenerative growth in human hear ...
STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health -
T7 RNA polymerase engineering and RNA amplification
SBC: Accacia International LLC Topic: N/ADESCRIPTION (provided by applicant): Expanding use of microarray systems for global gene expression profiling is leading biological research, providing diagnostic and prognostic value to physicians and facilitating target discovery during drug and vaccine development. There is strong interest in extending this microarray capability to more RNA-limited material to the point that a single cell can b ...
STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health -
GI safety and therapeutics of oil-based PC-NSAIDS
SBC: PLx Opco Inc. Topic: N/ADESCRIPTION (provided by applicant): In this Competing Continuation of our STTR Phase II grant, we propose to build upon the considerable progress made during the previous two funding cycles in our effort to develop a new family of phosphatidylcholine (PC)-associated nonsteroidal anti-inflammatory drugs (NSAIDs). During this period we have continued to develop our lead compounds, ibuprofen-PC and ...
STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health -
Personalized speech output for communication devices
SBC: Agora Net Inc Topic: N/ADESCRIPTION (provided by applicant): This project encompasses development and testing of a concatenative text-to-speech (TTS) synthesis system known as ModelTalker and software called InvTool which guides individuals in creating personal synthetic voices for use with ModelTalker. The overall system is intended to be of particular interest to Augmentative and Alternative Communication (AAC) device ...
STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health